Molecular mechanisms of drug resistance and its reversal in cancer

References

• Adan-Gokbulut A, Kartal-Yandim M, Iskender G, Baran Y. (2013). Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem, 20, 108–22
   PubMed Web of Science ®Google Scholar
• Ali IU, Schriml LM, Dean M. (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst, 91, 1922–32
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 39, 361–98
   PubMed Web of Science ®Google Scholar
• Annereau JP, Szakács G, Tucker CJ, et al. (2004). Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol, 66, 1397–405
   PubMed Web of Science ®Google Scholar
• Balkin ER, Jia F, Miller WH, Lewis MR. (2011). In vitro evaluation of targeted antisense 177Lu radiotherapy. Anticancer Res, 31, 3143–9
   PubMed Web of Science ®Google Scholar
• Barker CJ, Bowler K. (1991). Lipid composition of the membranes from cells of two rat tumors and its relationship to tumor thermosensitivity. Radiat Res, 125, 48–55
   PubMed Web of Science ®Google Scholar
• Bektas M, Jolly PS, Müller C, et al. (2005). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene, 24, 178–87
   PubMed Web of Science ®Google Scholar
• Bode AM, Dong Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer, 4, 793–805
   PubMed Web of Science ®Google Scholar
• Bogman K, Peyer AK, Török M, et al. (2001). HMG-CoAreductase inhibitors and P-glycoprotein modulation. Br J Pharmacol, 132, 1183–92
   PubMed Web of Science ®Google Scholar
• Borst P. (1991). Genetic mechanisms of drug resistance: a review. Acta Oncol, 30, 87–105
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst, 92, 1295–301
   PubMed Web of Science ®Google Scholar
• Campos L, Guyotat D, Archimbaud E, et al. (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473–6
   PubMed Web of Science ®Google Scholar
• Castaing M, Brouant P, Loiseau A, et al. (2000). Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge. J Pharm Pharmacol, 52, 289–96
   PubMed Web of Science ®Google Scholar
• Chang EH, Pirollo KF, Bouker KB. (2000). Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today, 6, 358–64
   PubMedGoogle Scholar
• Chauhan PS, Bhushan B, Singh LC, et al. (2012). Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol, 92, 44–9
   PubMed Web of Science ®Google Scholar
• Choi CH. (2005). ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int, 30, 1–13
   Google Scholar
• Cuestas ML, Sosnik A, Mathet V. (2011). Poloxamines display a multiple inhibitory activity of ATP-Binding Cassette (ABC) transporters in cancer cell lines. Mol Pharm, 8, 1152–64
   PubMed Web of Science ®Google Scholar
• Daniel C, Bell C, Burton C, et al. (2013). The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochimica et Biophysica Acta, 1832, 606–17
   Google Scholar
• Das M, Sahoo SK. (2012). Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One, 7, e32920
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Alliknets R. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res, 11, 1156–66
   PubMed Web of Science ®Google Scholar
• Demant EJ, Sehested M, Jensen PB. (1990). A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated transport in multidrug-resistant tumor cells. Biochim Biophys Acta, 1055, 117–25
   PubMed Web of Science ®Google Scholar
• Dönmez Y, Gündüz U. (2011). Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother, 65, 85–9
   PubMed Web of Science ®Google Scholar
• Doudican NA, Byron SA, Pollock PM, Orlow SJ. (2013). XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs, 24, 181–8
   PubMed Web of Science ®Google Scholar
• Duvvuri M, Krise JP. (2005). Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci, 10, 1499–509
   PubMed Web of Science ®Google Scholar
• Eid SY, El-Readi MZ, Eldin EE, et al. (2013). Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells. Phytomedicine, 21, 47–61
   PubMed Web of Science ®Google Scholar
• Fujita T, Doihara H, Washio K, et al. (2006). Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs, 17, 455–62
   PubMed Web of Science ®Google Scholar
• Gawryluk JW, Wang JF, Andreazza AC, et al. (2011). Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol, 14, 123–30
   PubMed Web of Science ®Google Scholar
• George SR, Ng GY, Lee SP, et al. (2003). Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: novel strategy for functional inhibition of membrane proteins in vivo. J Pharmacol Exp Ther, 307, 481–9
   PubMed Web of Science ®Google Scholar
• Giaccone G, Pinedo HM. (1996). Drug resistance. Oncologist, 1, 82–7
   PubMedGoogle Scholar
• Goldstein LJ, Galski H, Fojo A, et al. (1989). Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst, 81, 116–24
   PubMed Web of Science ®Google Scholar
• Gottesman MM. (2002). Mechanisms of cancer drug resistance. Ann Rev Med, 53, 615–27
   PubMed Web of Science ®Google Scholar
• Gouazé V, Liu YY, Prickett CS, et al. (2005). Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res, 65, 3861–7
   PubMed Web of Science ®Google Scholar
• Grant CE, Valdimarsson G, Hipfner DR, et al. (1994). Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res, 54, 357–61
   PubMed Web of Science ®Google Scholar
• Grasberger BL, Lu T, Schubert C, et al. (2005). Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem, 48, 909–12
   PubMed Web of Science ®Google Scholar
• Hao YX, He ZW, Zhu JH, et al. (2012). Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene. Chin Med J (Engl), 125, 2741–5
   PubMed Web of Science ®Google Scholar
• Hapke G, Yin MB, Rustum YM. (2001). Targeting molecular signals in chk1 pathways as a new approach for overcoming drug resistance. Cancer Metastasis Rev, 20, 109–15
   PubMed Web of Science ®Google Scholar
• Honda R, Tanaka H, Yasuda H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett, 420, 25–7
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, et al. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res, 64, 2333–7
   PubMed Web of Science ®Google Scholar
• Hu W, Kavanagh JJ. (2003). Anticancer therapy targeting the apoptotic pathway. Lancet Oncol, 4, 721–9
   PubMed Web of Science ®Google Scholar
• Kartal-Yandim M, Apohan E, Baran Y. (2013). Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer. Cancer Chemother Pharmacol, 71, 13–20
   PubMed Web of Science ®Google Scholar
• Kitazono M, Okumura H, Ikeda R, et al. (2001). Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer, 91, 126–31
   PubMed Web of Science ®Google Scholar
• Koblish HK, Zhao S, Franks CF, et al. (2006). Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther, 5, 160–9
   PubMed Web of Science ®Google Scholar
• Kool M, de Haas M, Scheffer GL, et al. (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res, 57, 3537–47
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. (2000). Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11, 265–83
   PubMed Web of Science ®Google Scholar
• Kruh GD, Belinsky MG. (2003). The MRP family of drug efflux pumps. Oncogene, 22, 7537–52
   PubMed Web of Science ®Google Scholar
• Kumar A, Kant S, Singh SM. (2013). Targeting monocarboxylate transporter by α-cyano-4-hydroxycinnamate modulates apoptosis and cisplatin resistance of Colo205 cells: implication of altered cell survival regulation. Apoptosis, 18, 1574–85
   PubMed Web of Science ®Google Scholar
• Kunze D, Erdmann K, Froehner M, et al. (2012). siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells. Anticancer Res, 32, 4313–18
   PubMed Web of Science ®Google Scholar
• Lamoureux F, Thomas C, Crafter C, et al. (2013). Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res, 19, 833–44
   PubMed Web of Science ®Google Scholar
• Larsen AK, Escargueil AE, Skladanowski A. (2000). Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther, 85, 217–29
   PubMed Web of Science ®Google Scholar
• Larsen AK, Skladanowski A. (1998). Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochem Biophys Acta, 1400, 257–74
   PubMed Web of Science ®Google Scholar
• Laurie NA, Donovan SL, Shih CS, et al. (2006). Inactivation of the p53 pathway in retinoblastoma. Nature, 444, 61–6
   PubMed Web of Science ®Google Scholar
• Leach MO. (1996). Introduction to in vivo MRS of cancer: new perspectives and open problems. Anticancer Res, 16, 1503–14
   PubMed Web of Science ®Google Scholar
• Leonard GD, Fojo T, Bates SE. (2003). The role of ABC transporters in clinical practice. Oncologist, 8, 411–24
   PubMed Web of Science ®Google Scholar
• Li J, Li ZN, Du YJ, et al. (2009). Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer, 10, 414–21
   PubMed Web of Science ®Google Scholar
• Li K, Chen B, Xu L, et al. (2013). Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine, 8, 1867–77
   PubMed Web of Science ®Google Scholar
• Liedert B, Materna V, Schadendorf D, et al. (2003). Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum- DNA adducts and decreased G2-arrest in melano.ma cells resistant to cisplatin. J Invest Dermatol, 121, 172–6
   PubMed Web of Science ®Google Scholar
• Lin S, Hoffmann K, Xiao Z, et al. (2013). MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int, 13, 1–10
   PubMed Web of Science ®Google Scholar
• Liscovitch M, Lavie Y. (2002). Cancer multidrug resistance: a review of recent drug discovery research. IDrugs, 5, 349–55
   PubMedGoogle Scholar
• Luqmani YA. (2005). Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract, 14, 35–48
   PubMed Web of Science ®Google Scholar
• Lv J, Tian Y. (2012). Effect of Src tyrosine kinase inhibition on the drug-resistance as well as MDR1 and LRP expression of the human cis-platinum-resistant lung cancer cell line A549/DDP. Zhongguo Fei Ai Za Zhi, 15, 501–6
   PubMedGoogle Scholar
• Maurer BJ, Melton L, Billups C, et al. (2000). Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst, 92, 1897–909
   PubMed Web of Science ®Google Scholar
• Mechetner EB, Roninson IB. (1992). Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA, 89, 5824–8
   PubMed Web of Science ®Google Scholar
• Merchant TE, Meneses P, Gierke LW, et al. (1991). 31P magnetic resonance phospholipid profiles of neoplastic human breast tissues. Br J Cancer, 63, 693–8
   PubMed Web of Science ®Google Scholar
• Merchant TE, de Graaf PW, Minsky BD, et al. (1993). Esophageal cancer phospholipid characterization by 31P NMR. NMR Biomed, 6, 187–93
   PubMed Web of Science ®Google Scholar
• Merchant TE, Diamantis PM, Lauwers G, et al. (1995). Characterization of malignant colon tumors with 31P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles. Cancer, 76, 1715–23
   PubMed Web of Science ®Google Scholar
• Millward MJ, Cantwell BM, Munro NC, et al. (1993). Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer, 67, 1031–5
   PubMed Web of Science ®Google Scholar
• Mulder GJ, Ouwerkerk-Mahadevan S. (1997). Modulation of glutathione conjugation in vivo: how to decrease glutathione conjugation in vivo or in intact cellular systems in vitro. Chem Biol Interact, 105, 17–34
   PubMed Web of Science ®Google Scholar
• Natarajan K, Xie Y, Baer RMT, Ross DR. (2012). Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol, 83, 1084–103
   PubMed Web of Science ®Google Scholar
• Ni Z, Bikadi Z, Rosenberg MF, Mao Q. (2010). Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab, 11, 603–17
   PubMed Web of Science ®Google Scholar
• O’Brien ML, Tew KD. (1996). Glutathione and related enzymes in multidrug resistance. Eur J Cancer, 32, 967–78
   Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer, 4, 604–16
   PubMed Web of Science ®Google Scholar
• Ozben T. (2006). Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett, 580, 2903–9
   PubMed Web of Science ®Google Scholar
• Palaniyandi K, Zhao Q, Chang XB. (2011). Infection of H69AR cells with retroviral particles harboring interfering RNAi significantly reduced the multidrug resistance of these small cell lung cancer cells. Int J Biochem Mol Biol, 2, 155–67
   PubMedGoogle Scholar
• Panagiotopoulou V, Richardson G, Jensen OE, Rauch C. (2010). On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the “space-time” dimension of MDR. Eur Biophys J, 39, 201–11
   Google Scholar
• Patel J, Mitra AK. (2001). Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics, 2, 401–15
   PubMedGoogle Scholar
• Pchejetski D, Golzio M, Bonhoure E, et al. (2005). Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res, 65, 11667–75
   PubMed Web of Science ®Google Scholar
• Pichler A, Zelcer N, Prior JL, et al. (2005). In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res, 11, 4487–94
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Bouker KB, Chang EH. (2000). Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs, 11, 419–32
   PubMed Web of Science ®Google Scholar
• Pluquet O, Hainaut P. (2001). Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett, 174, 1–15
   PubMed Web of Science ®Google Scholar
• Ponnusamy S, Meyers-Needham M, Senkal CE, et al. (2010). Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol, 6, 1603–24
   PubMed Web of Science ®Google Scholar
• Prajapati R, Sangamwar AT. (2014). Translocation mechanism of P-glycoprotein and conformational changes occurring at drug-binding site: insights from multi-targeted molecular dynamics. Biochim Biophys Acta, 1838, 2882–98
   PubMed Web of Science ®Google Scholar
• Prinetti A, Millimaggi D, D'Ascenzo S, et al. (2006). Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J, 395, 311–18
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Ross DD, Doyle LA, et al. (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res, 60, 47–50
   PubMed Web of Science ®Google Scholar
• Radin NS. (2002). The development of aggressive cancer: a possible role for sphingolipids. Cancer Invest, 20, 779–86
   PubMed Web of Science ®Google Scholar
• Rauch C. (2009). Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data, Eur Biophys J, 38, 829–46
   Google Scholar
• Rauch C, Pluen A. (2007). Multi drug resistance-dependent “vacuum cleaner” functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density, Eur Biophys J, 36, 121–31
   Google Scholar
• Reed JC. (1995). Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am, 9, 451–73
   PubMed Web of Science ®Google Scholar
• Riordan JR, Ling V. (1979). Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem, 254, 12701–5
   PubMed Web of Science ®Google Scholar
• Rooswinkel RW, van de Kooij B, Verheij M, Borst J. (2012). Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis, 3, e366
   PubMed Web of Science ®Google Scholar
• Saito G, Swanson JA, Lee KD. (2003). Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev, 55, 199–215
   PubMed Web of Science ®Google Scholar
• Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem, 73, 39–85
   PubMed Web of Science ®Google Scholar
• Sarkadi B, Müller M. (1997). Search for specific inhibitors of multidrug resistance in cancer. Sem Cancer Biol, 8, 171–82
   PubMed Web of Science ®Google Scholar
• Schisselbauer JC, Silber R, Papadopoulos E, et al. (1990). Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res, 50, 3562–68
   PubMed Web of Science ®Google Scholar
• Shah MA, Schwartz GK. (2001). Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res, 7, 2168–81
   PubMed Web of Science ®Google Scholar
• Sharom FJ, Yu X, Lu P, et al. (1999). Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol, 58, 571–86
   PubMed Web of Science ®Google Scholar
• Sherbakova EA, Stromskaia TP, Rybalkina EIU, et al. (2008). Role of PTEN protein in multidrug resistance of prostate cancer cells. Mol Biol, 42, 487–93
   Web of Science ®Google Scholar
• Simon S, Roy D, Schindler M. (1994). Intracellular pH and the control of multidrugresistance. Proc Natl Acad Sci USA, 91, 1128–32
   Google Scholar
• Smith ML, Seo YR. (2002). p53 regulation of DNA excision repair pathways. Mutagenesis, 17, 149–56
   PubMed Web of Science ®Google Scholar
• Stambolic V, Suzuki A, de la Pompa JL, et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95, 29–39
   PubMed Web of Science ®Google Scholar
• Stavrovskaya AA. (2000). Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry, 65, 95–106
   PubMed Web of Science ®Google Scholar
• Sun SH, Zheng M, Ding K, et al. (2008). A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther, 7, 845–52
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al. (2006). Targeting multidrug resistance in cancer. Nat Rev, 3, 219–34
   Google Scholar
• Szakács G, Annereau JP, Lababidi S, et al. (2004). Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell, 6, 129–37
   PubMed Web of Science ®Google Scholar
• Tew KD. (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res, 54, 4313–20
   PubMed Web of Science ®Google Scholar
• Veldman RJ, Mita A, Cuvillier O, et al. (2003). The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J, 17, 1144–6
   PubMed Web of Science ®Google Scholar
• Visentin B, Vekich JA, Sibbald BJ, et al. (2006). Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 9, 225–38
   PubMed Web of Science ®Google Scholar
• Walworth NC, Bernards R. (1996). Rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint. Science, 271, 353–6
   PubMed Web of Science ®Google Scholar
• Wang F, Li T, Zhang B, et al. (2013). MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun, 434, 688–94
   PubMed Web of Science ®Google Scholar
• Wang W, Rastinejad F, El-Deiry WS. (2003). Restoring p53-dependent tumor suppression. Cancer Biol Ther, 2, S55–63
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun Y. (2010). Targeting p53 for novel anticancer therapy. Transl Oncol, 3, 1–12
   PubMed Web of Science ®Google Scholar
• Xian XS, Park H, Choi MG, Park JM. (2013). Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant gastric cancer cells. Anticancer Res, 33, 2541–7
   PubMed Web of Science ®Google Scholar
• Xiao Z, Chen Z, Gunasekera AH, et al. (2003). Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem, 278, 21767–73
   PubMed Web of Science ®Google Scholar
• Yan XU, Feng ZHI, Guangming XU, et al. (2012). Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416. Biosci Rep, 32, 559–66
   PubMed Web of Science ®Google Scholar
• Yu HG, Ai YW, Yu LL, et al. (2008). Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer, 122, 433–43
   PubMed Web of Science ®Google Scholar
• Yu M, Ocana A, Tannock IF. (2013). Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev, 32, 211–27
   PubMed Web of Science ®Google Scholar
• Zhao BX, Sun YB, Wang SQ, et al. (2013). Grape seed procyanidin reversal of P-glycoprotein associated multi-drug resistance via down-regulation of NF-κb and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One, 8, e71071
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yu L, Lou F, et al. (1999). The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene (mrp) and mdr-1/p170 expression in acute leukemia. Zhonghua Nei Ke Za Zhi, 38, 760–3
   PubMedGoogle Scholar
• Zhu W, Shan X, Wang T, et al. (2010). miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer, 127, 2520–9
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhu D, Lu S, et al. (2012). miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol, 29, 384–91
   PubMed Web of Science ®Google Scholar